A Study To Investigate The Effect Of Inhaled Fluticasone Propionate On The Bronchial Responsiveness To Leukotriene D4 In Asthmatics Patients - Full Text View

A Study To Investigate The Effect Of Inhaled Fluticasone Propionate On The Bronchial Responsiveness To Leukotriene D4 In Asthmatics Patients

This study has been completed.

Sponsors and Collaborators:	GlaxoSmithKline None
Information provided by:	GlaxoSmithKline
ClinicalTrials.gov Identifier:	NCT00453778

Purpose

Investigate if asthmatics treated with FLIXOTIDE (FP) 500 mcg BID during 14 days get reduced bronchial reactivity after inhalation of Leukotriene D4. Two 14 days treatment periods where patients received FP 500 MCG BID and placebo. Washout at least 21 days between treatments. Bronchial challenge with methacholine and Leukotriene D4 were performed before the start of each treatment period and on treatment days 13 and 14 respectively.

Condition	Intervention
Mild Asthma	Drug: FLIXOTIDE Diskus 500 mcg (Fluticasone Propionate)

MedlinePlus related topics:

Asthma

ChemIDplus related topics:

Fluticasone Fluticasone propionate Methacholine Methacholine chloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Efficacy Study

Official Title:	A Study to Investigate the Effect of Inhaled Fluticasone Propionate on the Bronchial Responsiveness to Leukotriene D4 in Asthmatics Patients

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:

LTD4 PC20

Secondary Outcome Measures:

Shift in methacholine PD20

Estimated Enrollment:	14
Study Start Date:	January 2003

Eligibility

Ages Eligible for Study:	18 Years to 50 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion:

Diagnosed history of asthma
Non smoker last two years
< 5 pack years
FEV1 >70% of predicted
Mild and stable asthma
Only using short acting b2-agonist as rescue for the last 4 weeks
Have a history of atopy.

Exclusion:

Any significant respiratory disease, other than asthma
Subjects with seasonal asthma may not be included if they are in their season
Use of oral or inhaled glucocorticosteroid for the last 3 months and long-acting or oral b2-agonists, anticholinergic bronchodilators, cromones, antihistamines, theophyllines and antileukotrienes within two weeks
Upper or lower RTI within 6 weeks
Evidence of any disease that in the investigators mind would affect the results of the study
Participating in another study within 4 weeks
Females who are pregnant, intend to be or who are lactating
Methacholine PD20 > 454mcg
Negative scin prick test

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00453778

Locations


Sweden
	GSK Clinical Trials Call Center
	Stockholm, Sweden, SE17176

Sponsors and Collaborators

GlaxoSmithKline

None

Investigators


Principal Investigator:	GSK Clinical Trials, MD, prof.	GlaxoSmithKline

More Information

Study ID Numbers:	FMS40273, FMS40273
First Received:	March 27, 2007
Last Updated:	April 4, 2007
ClinicalTrials.gov Identifier:	NCT00453778
Health Authority:	Sweden: Medical Products Agency

Keywords provided by GlaxoSmithKline:

mild asthma

bronchial challenge

methacholine

leukotriene D4

FLIXOTIDE

Study placed in the following topic categories:

Methacholine Chloride

Fluticasone

Asthma

Additional relevant MeSH terms:

Anti-Inflammatory Agents

Respiratory System Agents

Autonomic Agents

Therapeutic Uses

Physiological Effects of Drugs

Anti-Asthmatic Agents

Anti-Allergic Agents

Peripheral Nervous System Agents

Dermatologic Agents

Bronchodilator Agents

Pharmacologic Actions

ClinicalTrials.gov processed this record on October 20, 2008